Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amid New M&A Rumors, Amarin CEO Focused On Vascepa Approval

Pfizer and Gilead Seen As Suitors

Executive Summary

 John Thero insists company is focused on approval and launch, as interest in European rights grow.

You may also be interested in...



New CV Outcomes Study May Mean Big Boost For Amgen's Repatha Market

The addressable patient population in the US could increase by 4.5 million if new trial is successful.

J&J’s Darzalex Scores Again In Frontline Myeloma

Janssen’s hemato-oncology success rolls on with impressive new overall survival data

As Bluebird’s CAR-T Competition Intensifies, Sickle Cell Therapy Brings Upside

While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141250

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel